Www.company.com 내과 R2 이지훈 N Engl J Med. 2014 Sep 8.

Slides:



Advertisements
Similar presentations
Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Advertisements

Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine.
UPLIFT Understanding Potential Long-term Impacts on Function with Tiotropium Adapted from Tashkin et al. NEJM 2008: 359: Please be advised that.
Planning, COPD Hot Topics and CSA preparation Ruth Gooch 11/1/12.
When to use the new LAB + LAMA combinations ?
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
Clinical Observation of Montelukast as a Partner Agent for Complementary Therapy.
Chronic obstructive pulmonary disease (COPD) Professor Bill MacNee
1 British Guideline on the Management of Asthma BTS/SIGN British Guideline on the Management of Asthma, May 2008 Introduction Diagnosis Non-pharmacological.
Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)
Bronchodilation is the cornerstone of treatment Pharmacological treatment of COPD.
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
Pulmonary and Allergy Drugs Advisory Committee January 17, 2002 Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17,
A 1 Pulmonary-Allergy Drugs Advisory Committee Meeting July 13, 2005 Safety of Long-acting Beta 2 -Agonists.
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Pulmonary-Allergy Drugs Advisory Committee Meeting July 13, 2005 Safety of.
Pulmonary-Allergy Drugs Advisory Committee January 17, FLOVENT ® DISKUS ® NDA , S004 GlaxoSmithKline Pulmonary-Allergy Drugs Advisory Committee.
Definition COPD def- A disease state characterized by air flow limitation that is not fully reversible It is expected to be the 3 rd leading cause of.
1 COPD Phenotypes Stephen I Rennard University of Nebraska Florianopolis, Brazil October 2009.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
ICSA2007 Symposium, 6/5/07 Panel Session Shuyen Ho First Example in Respiratory Area  Steroid Nasal Spray  Seasonal Allergic Rhinitis, Age  12 yr 
A 1 Physician’s Perspective: The Impact. A 2 Clinician’s Perspective Bartolome R. Celli, MD Professor of Medicine Tufts University Boston, MA.
INPULSIS® trial design and baseline characteristics
Pulmonary-Allergy Drugs Advisory Committee September 6, SGRQSGRQ 3 Domains: –Symptoms: cough, sputum production, wheeze, breathlessness, duration.
STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.
OFEV ® (nintedanib) TOMORROW trial results Last updated These slides are provided by Boehringer Ingelheim for medical to medical education only.
Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 OutlineOutline History of development programHistory of development program –Dr. Carol Bosken Introduction.
History Taking Zinc code: UKACL1878ea Date of preparation May 2015 AstraZeneca provided funding & reviewed for technical accuracy.
COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,
Tiotropium Bromide as an Adjunct Therapy to Inhaled Corticosteroids in the Treatment of Adults with Chronic Asthma Kevin Dennis Pacific University School.
Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma Stephen P. Peters, M.D., Ph.D., Susan J. Kunselman, M.A., Nikolina Icitovic, M.A.S.,
Lancet Respir Med 2013; 1: 199–209 R4.신재령 / Prof. 박명재
LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,
Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.
Analysis of chronic obstructive pulomnary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK):
Date of download: 6/2/2016 From: Internet-Based Self-management Plus Education Compared With Usual Care in Asthma: A Randomized Trial Ann Intern Med. 2009;151(2):
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
Patient-Reported Outcome (PRO) Claims in Products Approved For Chronic Obstructive Pulmonary Disease (COPD) in Europe and the USA Martine Caron, Laure-Lou.
A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation Michael Camilleri, M.D., Rene Kerstens, M.Sc., An Rykx, Ph.D., and Lieve Vandeplassche,
1 Once-daily indacaterol versus twice-daily salmeterol for COPD ; a placebo-controlled comparison R2 정명화 Eur Respir J 2011; 37: 273–279.
Safety of long-acting β-agonists for the treatment of asthma : clearing the air 장 나 은 Gustavo J Rodrigo, Jose A Castro-Rodrıguez Thorax 2012;
N Engl J Med 2012 ; 367 : Huib A.M. Kerstjens, M.D., Michael Engel, M.D., Ronald Dahl, M.D., Pierluigi Paggiaro, M.D., Ekkehard Beck, M.D.,
GOLD 2017 major revision: Summary of key changes
Thank you for viewing this presentation.
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE):
Poster No: PA972 Riley JH1, Fahy WA2, Vahdati-Bolouri M2, Tabberer M2
Research where it is most needed National Respiratory Strategy
Volume 149, Issue 5, Pages (May 2016)
Practical Recommendations for COPD:
The Role of Anticholinergic Therapy in Moderate to Severe Asthma
The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD
Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to previous chronic obstructive.
Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice.
What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?
Volume 153, Issue 4, Pages (April 2018)
Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma  Christian Vogelberg, MD, PhD, Michael Engel, MD, István.
The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial  Pierluigi Paggiaro,
Volume 152, Issue 6, Pages (December 2017)
Long-Acting Agents in Severe COPD
Personalizing COPD Therapy According to Recent Clinical Trial Evidence
A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.
Roflumilast in aggiunta ai broncodilatatori a lunga durata d’azione
Roflumilast negli studi di Fase III: i dati di efficacia
The efficacy and safety of omalizumab in pediatric allergic asthma
Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to previous chronic obstructive pulmonary.
Roflumilast: il programma di sviluppo clinico
Forest plot meta-analysis of the impact of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations on changes in.
Roflumilast in aggiunta ai corticosteroidi inalatori
Practical Recommendations for COPD:
Adjusted mean±se response in peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) at week 24, following once-daily tiotropium Respimat.
Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.
Presentation transcript:

내과 R2 이지훈 N Engl J Med Sep 8

INTRODUCTION EXACERBATIONS OF COPD –Lead to a change in treatment –Accelerated decline in lung function and health status –TREATMENT Inhaled glucocorticoids long-acting β-agonist (LABA) Long-acting muscarinic antagonists (LAMAs) –The benefit of inhaled glucocorticoids in addition to two long- acting bronchodilators has not been fully explored –Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management (WISDOM) trial

METHODS STUDY DESIGN –From February 2009 through July 2013 –multinational, randomized, doubleblind, parallel-group, active- control study –Run-in period (6-week) 18 μg of tiotropium once daily 50 μg of salmeterol xinafoate twice daily 500 μg of fluticasone propionate twice daily –Study period (52-week) stepwise reduction in the fluticasone dose every 6 weeks a total daily dose of 1000 μg to 500 μg, then to 200 μg, and finally to 0 μg (placebo)

METHODS WISDOM Study Design

METHODS PATIENTS –From February 2009 through July 2013 –multinational, randomized, doubleblind, parallel-group, active- control study –Run-in period (6-week) 18 μg of tiotropium once daily 50 μg of salmeterol xinafoate twice daily 500 μg of fluticasone propionate twice daily –Study period (52-week) stepwise reduction in the fluticasone dose every 6 weeks a total daily dose of 1000 μg to 500 μg, then to 200 μg, and finally to 0 μg (placebo)

METHODS END POINTS AND ASSESSMENTS –Primary End Point Time to 1st moderate or severe ontreatment COPD exacerbation during 12-month study period –Secondary End Points The time to the first severe COPD exacerbation The number of moderate or severe COPD exacerbations The change from baseline in lung function (including the trough FEV1, forced vital capacity, and peak expiratory flow rate) Health status - St. George’s Respiratory Questionnaire(SGRQ) Dyspnea - modified Medical Research Council (mMRC) scale

RESULTS

RESULTS

RESULTS PRIMARY ENDPOINT

RESULTS SECONDARY ENDPOINTS –Event rate : 0.95/patient-year vs. 0.91/patient-year

RESULTS SECONDARY ENDPOINTS –FEV1 38ml 43ml

RESULTS SECONDARY ENDPOINTS –HEALTH STATUS mMRC score –At week 18 : vs points (P=0.36) –At week 52 : vs points (P=0.06) SGRQ score –At week 27 : vs (P=0.08) –At week 52 : vs (P=0.047)

RESULTS SAFETY

RESULTS

DISCUSSION No notable differences in COPD exacerbations A small but significant and persistent between-group difference in the FEV1 No significant effect of glucocorticoid withdrawal on the mMRC score, but there was a difference in the total SGRQ score No significant between-group difference in the safety profile